Skip to main content

Hemolytic Uremic Syndrome News

FDA Approves Bkemv (eculizumab-aeeb), an Interchangeable Biosimilar to Soliris

May 28, 2024 – Today, the U.S. Food and Drug Administration approved Bkemv (eculizumab-aeeb) as the first interchangeable biosimilar to Soliris (eculizumab) to treat certain rare diseases. Bkemv is...

Utah Kids Got E. Coli From Playing Around Lawn Sprinklers

FRIDAY, May 10, 2024 – Happily jumping around lawn sprinklers or playing with garden hoses on a hot summer day: An idyllic childhood scene. Not so for a bunch of kids in Utah, who all got serious E....

Alexion Receives FDA Approval for Ultomiris (ravulizumab-cwvz) for Atypical Hemolytic Uremic Syndrome (AHUS)

BOSTON October 18, 2019 --(BUSINESS WIRE)--Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced that the U.S. Food and Drug Administration (FDA) approved Ultomiris (ravulizumab-cwvz) for the...

FDA Medwatch Alert: Soliris (eculizumab) Concentrated Solution for IV Infusion by Alexion: Recall - Visible Particulates

ISSUE: Alexion Pharmaceuticals, Inc. announced that it is initiating a voluntary recall of certain lots of Soliris (eculizumab) 300mg/30 mL concentrated solution for intravenous infusion. The...

Soliris (eculizumab) Approved by FDA for All Patients with Atypical Hemolytic Uremic Syndrome (aHUS)

CHESHIRE, Conn.--(BUSINESS WIRE)--Sep 23, 2011 - Alexion Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved Soliris® (eculizumab) for the treatment of ...

Ask a question

To post your own question to this support group, sign in or create an account.